Project Grant R01CA285582
Award Date
12/11/24
Completion Date
12/31/29
Dollars Obligated
$621K
Federal Agency
National Cancer Institute
Federal Grant Program
93.396
Assistance Type
Project Grant
Place of Performance
Boston, MA 02114, USA
Similar Awards
The National Cancer Institute (NCI) awarded a $2,104,477 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to study resistance mechanisms and enhance response to immune checkpoint blockade in central nervous system (CNS) metastases from breast cancer. The project aims to characterize the co-evolution of cancer and the immune system during immunotherapy in CNS metastases by profiling...
This federal Project Grant award from the National Cancer Institute (NCI) under the Cancer Research Manpower (CFDA 93.398) program provides $176,040 to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), from April 1, 2025 to March 31, 2027. The grant supports research to investigate the impact of aging on conventional type 1 dendritic cells (cDC1s) and their role in guiding CD8+ T cell immunity in the tumor microenvironment. The research aims to gain a...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides approximately $693,781 to The General Hospital Corporation (doing business as Massachusetts General Hospital) to conduct research aimed at harnessing mutant IDH1 as a therapeutic target for liver cancer, brain tumors, and other solid malignancies. The research program has two key components: Further studying how mutations in the IDH1 gene and the resulting metabolite...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $249,645 to The Children's Hospital Corporation (doing business as Boston Children's Hospital) to conduct advanced genetic engineering research to unravel tumor-specific B cell responses. The goal is to rapidly generate tumor-specific B cells that can be used to study the role of antigen-specific B cells in tumor progression, with the ultimate aim of developing innovative...
This Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $1,181,683 to the Dana-Farber Cancer Institute in Boston, MA to conduct research aimed at enhancing immune checkpoint blockade responsiveness and tertiary lymphoid structure formation through CD4+TFHx13 CAR-T cells to achieve cures for clear cell renal cell carcinoma (CCRCC). The research will involve experimental design and computational analysis of...
This federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $1,498,368.00 to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to elucidate molecular mechanisms of tumor-immune dynamics and evolution in response to radiation therapy for high- and very high-risk prostate cancer. The award, effective August 1, 2024 through July 31, 2027, will support cutting-edge...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), totaling $858,186 from May 1, 2025 to April 30, 2030. The project aims to decipher the mechanisms leading to immune-related myocarditis, a fatal adverse event associated with immune checkpoint inhibitor cancer therapy, and identify mitigation...
This Project Grant award from the National Institute of Biomedical Imaging and Bioengineering (NIBIB), under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286), aims to develop deep learning models to predict response to immune checkpoint inhibitor (ICI) therapy in patients with brain metastases. The total funding for this 4-year award is $194,022. The key objectives are to: 1) Develop a deep learning model using pre-treatment brain MRI...
This Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $689,934 to the Dana-Farber Cancer Institute (DFCI) to conduct research on the genetic factors underlying immune-related adverse events (IRAEs) associated with immune checkpoint inhibitor (ICI) cancer treatments. The key objectives are to: 1) Perform the largest genome-wide association study (GWAS) of IRAEs across over 13,000 ICI-treated patients, to identify shared and...
This federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $1,270,020.00 to The General Hospital Corporation (doing business as Massachusetts General Hospital) to conduct research on the development of personalized cancer vaccines targeting tumor heterogeneity and reprogramming the cold tumor micro-environment in kidney cancer. The award runs from July 1, 2025 through June 30, 2029. As a leading academic...